AR123029A2 - Compuestos de fenilimidazol - Google Patents
Compuestos de fenilimidazolInfo
- Publication number
- AR123029A2 AR123029A2 ARP210102048A ARP210102048A AR123029A2 AR 123029 A2 AR123029 A2 AR 123029A2 AR P210102048 A ARP210102048 A AR P210102048A AR P210102048 A ARP210102048 A AR P210102048A AR 123029 A2 AR123029 A2 AR 123029A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- group
- bond
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un compuesto (agente quimioterapéutico) eficaz para la prevención y tratamiento de hiperlipidemia, obesidad, o similares. Un compuesto de fenilimidazol o una sal farmacéuticamente aceptable del mismo representado por la siguiente fórmula (1). Reivindicación 1: Un compuesto de fenilimidazol caracterizado porque es representado por la siguiente fórmula (1) o una sal farmacéuticamente aceptable del mismo, donde R¹ es (1-1) hidrógeno, (1-2) pirazolilo, (1-3) pirimidinilo, (1-4) piridilo que tiene uno o dos sustituyentes seleccionados en cada caso en forma independiente entre el grupo que consiste en halógeno, ciano, C₁-C₆ alquilo, C₁-C₆ alquilsulfonilo, y C₁-C₆ alquilo sustituido con halógeno, (1-5) oxazolilo que tiene uno o más grupos C₁-C₆ alquilo, (1-6) pirazinilo opcionalmente sustituido con al menos un grupo seleccionado entre el grupo que consiste en halógeno y C₁-C₆ alquilo, (1-7) fenilo que tiene uno o dos sustituyentes seleccionados en cada caso en forma independiente entre el grupo que consiste en halógeno y C₁-C₆ alquilo sustituido con halógeno, (1-8) (1-óxido de piridin)ilo que tiene uno o dos sustituyentes seleccionados en cada caso en forma independiente entre el grupo que consiste en halógeno y C₁-C₆ alquilo sustituido con halógeno, (1-9) tiazolilo sustituido con halógeno, (1-10) isoxazolilo sustituido con C₁-C₆ alquilo, (1-11) 1,2,4-oxadiazolilo sustituido con C₃-C₈ cicloalquilo, o (1-12) fenilo; R² representa hidrógeno o C₁-C₆ alcoxi; R³ es (3-1) hidrógeno, (3-2) C₁-C₆ alcoxi, (3-3) C₁-C₆ alcoxiC₁-C₆ alcoxi, (3-4) C₁-C₆ alquilo, (3-5) halógeno, (3-6) benciloxi, o (3-7) hidroxi; R⁴ es (4-1) piridilo que tiene opcionalmente al menos un sustituyente seleccionado entre el grupo que consiste en halógeno, ciano, hidroxi, pirrolidinilo, C₁-C₆ alquilo, C₁-C₆ alquiltio, C₁-C₆ alquilsulfonilo, C₁-C₆ alcoxi, y C₁-C₆ alquilo sustituido con halógeno, (4-2) C₃-C₁₀ cicloalquilo que tiene opcionalmente uno o dos sustituyentes seleccionados en cada caso en forma independiente entre el grupo que consiste en halógeno y C₁-C₆ alquilo, o (4-3) alquilo inferior; R⁵ es (5-1) hidrógeno, (5-2) C₁-C₆ alquilo, o (5-3) C₁-C₆ alcoxi; R⁶ es (6-1) hidrógeno, (6-2) C₁-C₆ alcoxiC₁-C₆ alquilo, o (6-3) C₁-C₆ alquilo opcionalmente sustituido con uno o más grupos C₃-C₁₀ cicloalquilo, donde R⁶ se une a solamente uno de N en la posición 1 y N en la posición 3 del esqueleto imidazol, R⁶ se une a N en la posición 1 cuando el enlace entre N en la posición 3 y C en la posición 2 del esqueleto imidazol es un enlace doble, y R⁶ se une a N en la posición 3 cuando el enlace entre N en la posición 3 y C en la posición 2 del esqueleto imidazol es un enlace simple; R⁷ es (7-1) hidrógeno, (7-2) halógeno, (7-3) C₁-C₆ alquilo, (7-4) hidroximetilo, (7-5) C₁-C₆ alquilo sustituido con halógeno, o (7-6) ciano; A es un enlace simple cuando R¹ es hidrógeno, y A es C₁-C₆ alquileno cuando R¹ es un grupo distinto de hidrógeno; en el esqueleto imidazol, el enlace entre C en la posición 2 y N en la posición 1 es un enlace simple cuando el enlace entre N en la posición 3 y C en la posición 2 es un enlace doble, y el enlace entre C en la posición 2 y N en la posición 1 es un enlace doble cuando el enlace entre N en la posición 3 y C en la posición 2 es un enlace simple; con la condición de que se excluye el compuesto representado por la fórmula (1) donde R¹ es un grupo de (1-7) o (1-12) y R⁴ es un grupo de (4-3).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015254016 | 2015-12-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123029A2 true AR123029A2 (es) | 2022-10-26 |
Family
ID=59089969
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160104014A AR107191A1 (es) | 2015-12-25 | 2016-12-23 | Compuestos de fenilimidazol |
| ARP210102048A AR123029A2 (es) | 2015-12-25 | 2021-07-21 | Compuestos de fenilimidazol |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160104014A AR107191A1 (es) | 2015-12-25 | 2016-12-23 | Compuestos de fenilimidazol |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10570117B2 (es) |
| EP (2) | EP4023640A1 (es) |
| JP (3) | JP6828899B2 (es) |
| KR (2) | KR102176505B1 (es) |
| CN (2) | CN113200962B (es) |
| AR (2) | AR107191A1 (es) |
| AU (2) | AU2016378154B2 (es) |
| CA (1) | CA3009485C (es) |
| DK (1) | DK3401310T3 (es) |
| ES (1) | ES2913488T3 (es) |
| HK (2) | HK1257221A1 (es) |
| HU (1) | HUE058875T2 (es) |
| MX (2) | MX2018007796A (es) |
| MY (1) | MY196907A (es) |
| PH (1) | PH12018501100A1 (es) |
| PL (1) | PL3401310T3 (es) |
| PT (1) | PT3401310T (es) |
| RU (1) | RU2715712C2 (es) |
| SG (1) | SG11201804310VA (es) |
| TW (2) | TWI780557B (es) |
| WO (1) | WO2017110237A1 (es) |
| ZA (1) | ZA201803419B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3190455A1 (en) * | 2020-07-30 | 2022-02-03 | Otsuka Pharmaceutical Factory, Inc. | Cold medicine and antiviral medicine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4642311A (en) * | 1975-03-03 | 1987-02-10 | Merck & Co., Inc. | β-adrenergic blocking imidazolylphenoxy propanolamines |
| US4134983A (en) * | 1975-03-03 | 1979-01-16 | Merck & Co., Inc. | 3-amino-2-or-propoxyaryl substituted imidazoles |
| CA1075689A (en) * | 1976-07-23 | 1980-04-15 | John J. Baldwin | Substituted imidazoles, their preparation and use |
| AU518569B2 (en) | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
| US4443446A (en) | 1980-05-30 | 1984-04-17 | University Of Georgia Research Foundation, Inc. | Use of psychoactive drugs as vaginal contraceptives |
| US5861359A (en) * | 1995-07-25 | 1999-01-19 | Fmc Corporation | Herbicidal phenylmethoxphenyl heterocycles |
| US20110065728A1 (en) | 2008-05-14 | 2011-03-17 | Otsuka Pharmaceutical Factory, Inc. | Lipoprotein lipase-activating compositions comprising benzene derivatives |
| TWI435871B (zh) * | 2009-02-04 | 2014-05-01 | Otsuka Pharma Co Ltd | 苯基咪唑化合物 |
| JP6617155B6 (ja) * | 2015-04-07 | 2020-01-22 | グアンドン・レイノーヴェント・バイオテック・カンパニー・リミテッド | チロシンキナーゼ阻害剤およびそれを含む医薬組成物 |
-
2016
- 2016-10-25 CN CN202110542910.2A patent/CN113200962B/zh active Active
- 2016-10-25 US US15/780,436 patent/US10570117B2/en active Active
- 2016-10-25 SG SG11201804310VA patent/SG11201804310VA/en unknown
- 2016-10-25 EP EP22154136.0A patent/EP4023640A1/en active Pending
- 2016-10-25 PT PT168781359T patent/PT3401310T/pt unknown
- 2016-10-25 JP JP2017557761A patent/JP6828899B2/ja active Active
- 2016-10-25 KR KR1020187019298A patent/KR102176505B1/ko active IP Right Grant
- 2016-10-25 HU HUE16878135A patent/HUE058875T2/hu unknown
- 2016-10-25 WO PCT/JP2016/081633 patent/WO2017110237A1/ja active Application Filing
- 2016-10-25 MX MX2018007796A patent/MX2018007796A/es unknown
- 2016-10-25 DK DK16878135.9T patent/DK3401310T3/da active
- 2016-10-25 CN CN201680075936.8A patent/CN108430977B/zh active Active
- 2016-10-25 CA CA3009485A patent/CA3009485C/en active Active
- 2016-10-25 EP EP16878135.9A patent/EP3401310B1/en active Active
- 2016-10-25 AU AU2016378154A patent/AU2016378154B2/en active Active
- 2016-10-25 ES ES16878135T patent/ES2913488T3/es active Active
- 2016-10-25 MX MX2021010182A patent/MX2021010182A/es unknown
- 2016-10-25 KR KR1020207026083A patent/KR102318395B1/ko active Active
- 2016-10-25 RU RU2018127016A patent/RU2715712C2/ru active
- 2016-10-25 PL PL16878135T patent/PL3401310T3/pl unknown
- 2016-10-25 MY MYPI2018702118A patent/MY196907A/en unknown
- 2016-12-05 TW TW110100134A patent/TWI780557B/zh active
- 2016-12-05 TW TW105140091A patent/TWI721057B/zh active
- 2016-12-23 AR ARP160104014A patent/AR107191A1/es unknown
-
2018
- 2018-05-22 PH PH12018501100A patent/PH12018501100A1/en unknown
- 2018-05-23 ZA ZA2018/03419A patent/ZA201803419B/en unknown
- 2018-12-18 HK HK18116226.2A patent/HK1257221A1/zh unknown
- 2018-12-25 HK HK18116561.5A patent/HK1257353A1/zh unknown
-
2020
- 2020-10-28 AU AU2020260426A patent/AU2020260426B2/en active Active
- 2020-12-16 JP JP2020208041A patent/JP7224674B2/ja active Active
-
2021
- 2021-07-21 AR ARP210102048A patent/AR123029A2/es unknown
-
2022
- 2022-12-09 JP JP2022197190A patent/JP7554492B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110405A1 (es) | Compuestos | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR101367A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR094342A1 (es) | Derivados de ácido borónico útiles como agentes antimicrobianos | |
| AR094978A1 (es) | Derivados de pirazol agonistas de receptores canabinoides | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR105549A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| AR095421A1 (es) | Moduladores de p2x7 | |
| AR089753A1 (es) | Derivados de amida heterociclicos como antagonistas del receptor p2x7 | |
| AR102217A1 (es) | Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
| AR107428A1 (es) | COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC | |
| AR089623A1 (es) | Inhibidores de iap | |
| AR100439A1 (es) | Derivados de carboxamida | |
| EA201591645A1 (ru) | Hантагонисты, имеющие феноксипиперидиновое ядро в структуре | |
| AR091770A1 (es) | Indolcarbonitrilos moduladores selectivos de receptores androgenicos | |
| AR097252A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| AR097245A1 (es) | Derivado de pirazolilpirazol sustituido y su empleo como herbicida | |
| AR104262A1 (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3 quinasas | |
| AR100440A1 (es) | Derivados de carboxamida como inhibidores selectivos de smurf1 | |
| AR101132A1 (es) | Derivados de pirazina agonistas del gpr40 para el tratamiento de la diabetes tipo ii | |
| AR109108A1 (es) | Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2 | |
| AR114465A1 (es) | Compuestos de pirazol sustituidos con heteroarilo y su utilización farmacéutica |